MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ
5.45
-0.12
-2.15%
Pre Market: 5.32 -0.13 -2.39% 09:12 07/25 EDT
OPEN
5.48
PREV CLOSE
5.57
HIGH
5.67
LOW
5.33
VOLUME
119
TURNOVER
0
52 WEEK HIGH
23.07
52 WEEK LOW
3.610
MARKET CAP
195.90M
P/E (TTM)
-1.5287
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BMEA last week (0715-0719)?
Weekly Report · 3d ago
Weekly Report: what happened at BMEA last week (0708-0712)?
Weekly Report · 07/15 09:21
Scotiabank Keeps Their Buy Rating on Biomea Fusion (BMEA)
TipRanks · 07/11 11:05
Peek Under The Hood: IWC Has 48% Upside
NASDAQ · 07/08 14:22
Weekly Report: what happened at BMEA last week (0701-0705)?
Weekly Report · 07/08 09:22
Weekly Report: what happened at BMEA last week (0624-0628)?
Weekly Report · 07/01 09:22
Biomea Fusion Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 06/25 11:08
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $15 Price Target
Benzinga · 06/25 10:58
More
About BMEA
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).

Webull offers Biomea Fusion Inc stock information, including NASDAQ: BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.